A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Phase 2 Unknown 71 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, multi-center clinical trial to evaluate the safety and efficacy of TQ-B3139 capsules in patients with MET gene abnormal advanced non-small cell lung cancer.

Timeline

Start: 2020-08-11
Primary completion: 2022-01-31
Completion: 2022-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQ-B3139	Small molecule	600 mg	Oral

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications